Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

Abstract excerpt

BACKGROUND: New treatment options are needed to maintain and improve therapy for tuberculosis, which caused the death of 1.5 million people in 2013 despite potential for an 86 % treatment success rate. A greater understanding of Mycobacterium tuberculosis (M.tb) bacilli that persist through drug therapy will aid drug development programs. Predictive biomarkers for treatment efficacy are also a research priority....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacterial Genetics and Biotechnology
• Share to Mycobacterium research and diagnosis
• Share to Tuberculosis Research and Epidemiology